Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772456 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
A Phase 1 study of Glioma, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04772456 is a Phase 1 study of Glioma that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 5 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04772456, a Phase 1 study of Glioma, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
Study Locations (1)
Maryland
- Rosy Njonkou Tchoquessi - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04772456
The ClinicalTrials.gov registry entry for NCT04772456 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (98% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT04772456 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04772456 about?
NCT04772456 is a clinical study titled "Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas". The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added...
What is the current status of trial NCT04772456?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-08-11. Estimated completion is 2027-12-31.
What conditions does trial NCT04772456 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT04772456?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04772456?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04772456 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.